BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dieterle MG, Rao K, Young VB. Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections. Ann N Y Acad Sci 2019;1435:110-38. [PMID: 30238983 DOI: 10.1111/nyas.13958] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Dieterle MG, Putler R, Perry DA, Menon A, Abernathy-Close L, Perlman NS, Penkevich A, Standke A, Keidan M, Vendrov KC, Bergin IL, Young VB, Rao K. Systemic Inflammatory Mediators Are Effective Biomarkers for Predicting Adverse Outcomes in Clostridioides difficile Infection. mBio 2020;11:e00180-20. [PMID: 32371595 DOI: 10.1128/mBio.00180-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
2 Cruz KCP, Enekegho LO, Stuart DT. Bioengineered Probiotics: Synthetic Biology Can Provide Live Cell Therapeutics for the Treatment of Foodborne Diseases. Front Bioeng Biotechnol 2022;10:890479. [DOI: 10.3389/fbioe.2022.890479] [Reference Citation Analysis]
3 Guilleman MM, Stevens BAY, Van Lieshout LP, Rghei AD, Pei Y, Santry LA, Thompson B, Wootton SK. AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge. Gene Ther 2021. [PMID: 33608675 DOI: 10.1038/s41434-021-00236-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Du Y, Li X, Su C, Wang L, Jiang J, Hong B. The human gut microbiome - a new and exciting avenue in cardiovascular drug discovery. Expert Opin Drug Discov 2019;14:1037-52. [PMID: 31315489 DOI: 10.1080/17460441.2019.1638909] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Pomares Bascuñana RÁ, Veses V, Sheth CC. Effectiveness of fecal microbiota transplant for the treatment of Clostridioides difficile diarrhea: a systematic review and meta-analysis. Lett Appl Microbiol 2021;73:149-58. [PMID: 33864273 DOI: 10.1111/lam.13486] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Sullivan MH, Boggiano VL, Smith KL. Management of difficult-to-treat Clostridioides difficile in a patient with chronic osteomyelitis. BMJ Case Rep 2020;13:e233095. [PMID: 32229549 DOI: 10.1136/bcr-2019-233095] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Seeberger PH. Discovery of Semi- and Fully-Synthetic Carbohydrate Vaccines Against Bacterial Infections Using a Medicinal Chemistry Approach. Chem Rev 2021;121:3598-626. [PMID: 33794090 DOI: 10.1021/acs.chemrev.0c01210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Vasilescu I, Chifiriuc M, Pircalabioru GG, Filip R, Bolocan A, Lazăr V, Diţu L, Bleotu C. Gut Dysbiosis and Clostridioides difficile Infection in Neonates and Adults. Front Microbiol 2022;12:651081. [DOI: 10.3389/fmicb.2021.651081] [Reference Citation Analysis]
9 Ressler A, Wang J, Rao K. Defining the black box: a narrative review of factors associated with adverse outcomes from severe Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211048127. [PMID: 34646358 DOI: 10.1177/17562848211048127] [Reference Citation Analysis]
10 Knežević D, Petković M. Faecal transplantation and Clostridioides difficile infection. Scripta Medica 2021;52:215-23. [DOI: 10.5937/scriptamed52-32752] [Reference Citation Analysis]
11 Milner E, Stevens B, An M, Lam V, Ainsworth M, Dihle P, Stearns J, Dombrowski A, Rego D, Segars K. Utilizing Probiotics for the Prevention and Treatment of Gastrointestinal Diseases. Front Microbiol 2021;12:689958. [PMID: 34434175 DOI: 10.3389/fmicb.2021.689958] [Reference Citation Analysis]
12 Sleha R, Radochova V, Mikyska A, Houska M, Bolehovska R, Janovska S, Pejchal J, Muckova L, Cermak P, Bostik P. Strong Antimicrobial Effects of Xanthohumol and Beta-Acids from Hops against Clostridioides difficile Infection In Vivo. Antibiotics (Basel) 2021;10:392. [PMID: 33917416 DOI: 10.3390/antibiotics10040392] [Reference Citation Analysis]
13 Kachrimanidou M, Tsintarakis E. Insights into the Role of Human Gut Microbiota in Clostridioides difficile Infection. Microorganisms 2020;8:E200. [PMID: 32023967 DOI: 10.3390/microorganisms8020200] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
14 Rao K, Malani PN. Diagnosis and Treatment of Clostridioides (Clostridium) difficile Infection in Adults in 2020. JAMA 2020;323:1403-4. [PMID: 32150234 DOI: 10.1001/jama.2019.3849] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
15 Phanchana M, Phetruen T, Harnvoravongchai P, Raksat P, Ounjai P, Chankhamhaengdecha S, Janvilisri T. Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile. Sci Rep 2020;10:6497. [PMID: 32300130 DOI: 10.1038/s41598-020-63199-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Tomkovich S, Taylor A, King J, Colovas J, Bishop L, McBride K, Royzenblat S, Lesniak NA, Bergin IL, Schloss PD. An Osmotic Laxative Renders Mice Susceptible to Prolonged Clostridioides difficile Colonization and Hinders Clearance. mSphere 2021;6:e0062921. [PMID: 34585964 DOI: 10.1128/mSphere.00629-21] [Reference Citation Analysis]
17 Afouda P, Hocquart M, Pham TP, Kuete E, Ngom II, Dione N, Valles C, Bellali S, Lagier JC, Dubourg G, Raoult D. Alcohol pretreatment of stools effect on culturomics. Sci Rep 2020;10:5190. [PMID: 32251347 DOI: 10.1038/s41598-020-62068-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Li BY, Oh J, Young VB, Rao K, Wiens J. Using Machine Learning and the Electronic Health Record to Predict Complicated Clostridium difficile Infection. Open Forum Infect Dis 2019;6:ofz186. [PMID: 31139672 DOI: 10.1093/ofid/ofz186] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
19 Rajeshkumar NV, Kers JA, Moncrief S, Defusco AW, Park JH, Handfield M. Preclinical evaluation of the maximum tolerated dose and toxicokinetics of enteric-coated lantibiotic OG253 capsules. Toxicol Appl Pharmacol 2019;374:32-40. [PMID: 31034929 DOI: 10.1016/j.taap.2019.04.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Li T, Zhang Y, Dong K, Kuo CJ, Li C, Zhu YQ, Qin J, Li QT, Chang YF, Guo X, Zhu Y. Isolation and Characterization of the Novel Phage JD032 and Global Transcriptomic Response during JD032 Infection of Clostridioides difficile Ribotype 078. mSystems 2020;5:e00017-20. [PMID: 32371470 DOI: 10.1128/mSystems.00017-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Lesniak NA, Schubert AM, Sinani H, Schloss PD. Clearance of Clostridioides difficile Colonization Is Associated with Antibiotic-Specific Bacterial Changes. mSphere 2021;6:e01238-20. [PMID: 33952668 DOI: 10.1128/mSphere.01238-20] [Reference Citation Analysis]
22 Gnocchi M, Gagliardi M, Gismondi P, Gaiani F, De' Angelis GL, Esposito S. Updated Management Guidelines for Clostridioides difficile in Paediatrics. Pathogens 2020;9:E291. [PMID: 32316346 DOI: 10.3390/pathogens9040291] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]